Skip to main content
Retour
CBIO logo

Crescent Biopharma, Inc.

Qualité des données : 100%
CBIO
NASDAQ Healthcare Biotechnology
CEO: Joshua T. Brumm Employees: 41 IPO: Jan 10, 2014
Prix
18,37 €
Variation
▲ 1,75 €
10,53%
Cap. Boursière
506,22M
Fourchette du Jour
17,00 € 18,43 €
Fourchette 52 Semaines
8,72 € 29,00 €
Volume
199 217
Moyenne 50J / 200J
11,37 €
12,68 €
Clôture Précédente
16,62 €

Quick Summary

Points Clés

Revenue grew 74,87% annually over 5 years — strong growth
Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of -72,45M
PEG of 0,07 suggests growth is underpriced
Capital efficient — spends only 8,47% of revenue on capex

Croissance

Revenue Growth (5Y)
74,87%
Au-dessus de la moyenne du secteur (9,58%)
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-143,95%
En dessous de la moyenne du secteur (3,68%)
ROIC-55,93%
Net Margin-1382,72%
Op. Margin-1407,52%

Sécurité

Debt / Equity
0,01
En dessous de la moyenne du secteur (0,24)
Current Ratio6,56
Interest Coverage-69,85

Valorisation

P/E Ratio
-3,38
En dessous de la moyenne du secteur (0,23)
Forward P/EN/A
P/B Ratio2,49
EV/EBITDAN/A
Dividend Yield0,00%

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (635 pairs)

Métrique Action Médiane du Secteur
P/E -3,4 0,2
P/B 2,5 2,9
ROE % -144,0 3,7
Net Margin % -1382,7 3,9
Rev Growth 5Y % 74,9 9,6
D/E 0,0 0,2

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) 3193,02%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 74,87% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 10,84M Net Income (TTM) -149,94M
ROE -143,95% ROA -62,40%
Gross Margin 99,23% Operating Margin -1407,52%
Net Margin -1382,72% Free Cash Flow (TTM) -72,45M
ROIC -55,93% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,01 Current Ratio 6,56
Interest Coverage -69,85
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,38 Forward P/E N/A
P/B Ratio 2,49 P/S Ratio 46,68
PEG Ratio 0,07 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -14,31%
Market Cap 506,22M Enterprise Value 294,67M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 10,84M 0,0 10 000,0 75 000,0 1,16M
Net Income -149,94M -71,47M -36,90M -46,69M -63,43M
EPS (Diluted) 0,02 -0,59 -0,58 -0,89 -1,23
Gross Profit 10,76M -35 174,0 10 000,0 75 000,0 1,16M
Operating Income -152,63M -68,76M -39,28M -47,40M -63,45M
EBITDA -149,67M 0,0 -39,12M -47,20M -63,18M
R&D Expenses 138,09M 56,14M 20,07M 28,39M 47,49M
SG&A Expenses 25,39M 12,63M 19,21M 19,09M 17,12M
D&A 84 000,0 68,76M 153 301,0 207 145,0 264 600,0
Interest Expense 2,19M 0,0 0,0 0,0 0,0
Income Tax -2,00M 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 240,29M 35,62M 45,32M 51,81M 94,35M
Total Liabilities 37,28M 51,10M 6,90M 8,88M 12,74M
Shareholders' Equity 203,01M 5,31M 38,41M 42,93M 81,60M
Total Debt 1,64M 37,48M 808 402,0 918 555,0 1,92M
Cash & Equivalents 213,19M 34,77M 41,79M 47,87M 90,25M
Current Assets 236,66M 34,80M 43,79M 50,71M 90,79M
Current Liabilities 36,07M 9,61M 6,84M 8,88M 11,82M